Request for Proposals - Independent Medical Education

FcRn Inhibition for the Treatment of Myasthenia Gravis – Potential impact on Disease Management Paradigms

argenx supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, and education) to improve patient outcomes in areas of unmet medical need that are aligned with argenx medical and scientific strategies. Through this RFP, it is our intent to support CME/CE programs in the following areas of interest.

Areas of Interest

  • The rationale for targeted immune-mediated therapy in the treatment and management of gMG 
  • Understanding the mechanism of action of FcRn in the context of autoantibody mediated pathophysiology of gMG  
  • A review of recent clinical trial data for FcRn including long-term safety 
  • Potential impact of FcRn inhibitors on current international treatment guidance for gMG (e.g. earlier in disease course, steroid reducing strategies) 
  • Considerations for use of FcRn inhibitor therapy including optimal patient profile and dosing regimen

Program Format Considerations

  • Program to start after January 1st, 2024
  • A single program consisting of up to major neurology medical care centers across the US with preference for live in-person sessions; “Grand Rounds” format preferred
  • Enduring content for at least 12-months after launch of program.

RFP Timeline

  • We will be accepting proposals for this RFP until November 20th.

Target Audience

  • Minimum CME/CE requirement, 1 credit for all proposals 
  • Educational credits in North America MDs, NPs, PAs, PharmD/RPh in neurology, neuromuscular, or neuroimmunology disease space./li>

Questions or proposals regarding this RFP must be submitted to [email protected]

argenx grants

About argenx Grants:

Decisions for grants are made through a formal, grant review and decision-making process. The Grant Review Committee assesses and approves applications based upon need, design, scientific rigor, independence and compliance, Approvals depend on available funding, the volume of requests, and alignment with argenx’s areas of interest.

Together We Discover